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Abstract  32 
Rhythmic neural activity has been proposed to play a fundamental role in cognition. Both 33 
healthy and pathological aging are characterized by frequency-specific changes in oscillatory 34 
activity. However, the cognitive relevance of these changes across the spectrum from normal to 35 
pathological aging remains unknown. We examined electroencephalography (EEG) correlates 36 
of cognitive function in healthy aging and two of the most prominent and debilitating age-related 37 
disorders: Type-2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD). Relative to HC, AD 38 
patients were impaired on nearly every cognitive measure, while T2DM performed worse mainly 39 
on learning and memory tests. A continuum of alterations in resting-state EEG was associated 40 
with pathological aging, generally characterized by reduced alpha (α) and beta (β) power 41 
(AD<T2DM<HC) and increased delta (δ) and theta (θ) power (AD>T2DM>HC), with some 42 
variations across different brain regions. There were also reductions in the frequency and power 43 
density of the posterior dominant rhythm in AD. The ratio of (α+β)/(δ+θ) was specifically 44 
associated with cognitive function in a domain- and diagnosis-specific manner. The results thus 45 
captured both similarities and differences in the pathophysiology of cerebral oscillations in 46 
T2DM and AD. Overall, pathological brain aging is marked by a shift in oscillatory power from 47 
higher to lower frequencies, which can be captured by a single cognitively relevant measure of 48 
the ratio of (α+β) over (δ+θ) power.  49 
 50 
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Introduction  54 
Some subtle neurocognitive changes occur with normal aging (Harada et al., 2013), while 55 
others are more severe and associated with specific pathophysiological processes. The most 56 
extreme example is dementia due to Alzheimer’s disease (AD). AD is associated with 57 
progressive alterations including the accumulation of beta-amyloid plaques and neurofibrillary 58 
tangles, cortical hypometabolism, and eventually widespread atrophy (Braak and Braak, 1998; 59 
Jack et al., 2013). Among AD risk factors (Burns and Iliffe, 2009), one of the most prominent is 60 
Type-2 Diabetes Mellitus (T2DM) (Biessels and Kappelle, 2005). T2DM is a chronic metabolic 61 
disorder characterized by abnormal glucose metabolism and insulin resistance, and is 62 
associated with myriad physiological complications, including in the central nervous system 63 
(CNS) (Alberti and Zimmet, 1998; Awad et al., 2004; Biessels and Kappelle, 2005; Gispen and 64 
Biessels, 2000; Koekkoek et al., 2014; Roberts et al., 2014; Saedi et al., 2016; Stewart and 65 
Liolitsa, 1999; Strachan et al., 2011). Mild deficits in memory, executive function and perceptual 66 
processing speed have been observed in T2DM (Cheng et al., 2012; Marseglia et al., 2016; 67 
Mooradian et al., 1988; Palta et al., 2014; Takeuchi et al., 2012; van den Berg et al., 2010). 68 
While the impact of T2DM on the CNS is likely multifactorial, microvascular damage and 69 
impaired insulin signaling have been identified as probable mediators in the higher risk for AD 70 
and vascular dementias (Biessels et al., 2014; Ohara, 2011; Toth, 2014). However, 71 
understanding of how T2DM fits into the spectrum from normal cognitive aging to AD remains 72 
incomplete (de la Monte, 2014).  73 
Electroencephalography (EEG) permits noninvasive measurement of temporally 74 
synchronized (i.e., oscillatory) neural activity, a ubiquitous characteristic of the brain (Buzsaki et 75 
al., 2013) which has been proposed as a mechanism for encoding and transfer of information 76 
(Bonnefond et al., 2017; Fries, 2015). These proposals are based on reliable associations 77 
between frequency-specific oscillations and various cognitive functions (Ward, 2003), as well as 78 
their implication in various neuropsychiatric disorders (He et al., 2007; Oswal et al., 2013; 79 
 4 
Schnitzler and Gross, 2005; Uhlhaas and Singer, 2006). Systematic changes in neural 80 
oscillations occur with normal cognitive aging (Babiloni et al., 2006b; Marshall and Cooper, 81 
2017; Rossini et al., 2007; Stomrud et al., 2010; Vlahou et al., 2014). For instance, alpha-band 82 
(8-13 Hz) activity decreases in both amplitude (Babiloni et al., 2006b; Marshall and Cooper, 83 
2017) and peak frequency (Klimesch, 1999; Mierau et al., 2017; Knyazeva et al., 2018) 84 
throughout adulthood. However, changes in lower frequency (<8 Hz) activity, and the 85 
relationship with cognitive function, appear to be less consistent (Babiloni et al., 2006a; 86 
Cummins and Finnigan, 2007; Klass and Brenner, 1995; Leirer et al., 2011; Marshall and 87 
Cooper, 2017).  88 
         Oscillatory abnormalities have been consistently observed in pathological aging (Assenza 89 
et al., 2017; Babiloni et al., 2004, 2006a; Fraga et al., 2013; Neto et al., 2016; Voytek and 90 
Knight, 2015). In AD, the most prominent EEG finding is a shift in power from higher to lower 91 
frequencies: an increase in power in delta (δ; 1-4 Hz) and theta (θ; 4-8 Hz) frequency bands, 92 
and a concomitant decrease in power in alpha (α; 8-13 Hz) and beta (β; 13-30 Hz) bands, along 93 
with reduction of the individual peak α frequency (Babiloni et al., 2004; Bennys et al., 2001; 94 
Brenner et al., 1986; Coben et al., 1983; Moretti et al., 2004). The relationship between these 95 
oscillatory changes and cognitive dysfunction remains unclear, though some studies have 96 
reported correlations with individual tests of cognitive functions (Babiloni et al., 2007; Moretti et 97 
al., 2009; van der Hiele et al., 2007). While fewer studies have examined oscillatory changes in 98 
T2DM, there is some evidence of a similar shift in power from higher to lower frequencies (Bian 99 
et al., 2014; Cooray et al., 2011; Cui et al., 2014; Wen et al., 2016; Zeng et al., 2015). 100 
The aim of the current study was to compare resting-state EEG oscillatory activity, and 101 
its relationship with neuropsychological function, across healthy and pathological aging (T2DM 102 
and AD). We hypothesized that neuropsychological testing and resting-state oscillatory activity 103 
would reveal a pattern of neurocognitive dysfunction from healthy controls (HC) to T2DM to AD. 104 
Additionally, we predicted that resting-state EEG measures (i.e. power density and peak 105 
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frequencies) would be associated with domain-specific cognitive performance both within and 106 
across groups, with AD showing the strongest relationships (Babiloni et al., 2018, 2015).  107 
 108 
Methods and Materials 109 
Human Participants 110 
This is an analysis of 72 adults who participated in research at the Berenson-Allen Center for 111 
Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center between 2012 and 112 
2015. The local Institutional Review Board approved the study. All participants provided written 113 
informed consent prior to enrollment according to the Declaration of Helsinki. Participants were 114 
drawn from the following groups: 115 
Alzheimer’s disease. 18 participants (11 females, aged 52-86) with a probable diagnosis 116 
of mild-to-moderate AD according to DSM-V/NINCDS-ADRDA criteria (McKhann et al., 2011), 117 
with a clinical dementia rating (CDR) of 1.0 and a mini-mental status exam (MMSE) (Folstein et 118 
al., 1975) score between 18-24. Six patients were medicated with Cholinesterase inhibitors, 119 
nine were on Cholinesterase inhibitors and Memantine, while 3 were not taking dementia-120 
specific medications. 121 
Type-2 diabetes mellitus. 27 participants (12 females, aged 50-78) had a clinical 122 
diagnosis of T2DM, and had normal cognition as indicated by a MMSE score ≥ 27 (Rosa et al., 123 
2018), with no subjective cognitive complaints. All had their diabetes at least moderately 124 
controlled (hemoglobin A1c; HbA1c < 10) through some combination of diet, exercise, 125 
Metformin, insulin, or insulin homologues. 126 
Healthy control. 27 participants (13 females, aged 50-77) had normal cognition (MMSE ≥ 127 
27) and glucose metabolism (HbA1c < 6.5%).  128 
General inclusion criteria included: age-adjusted score ≥ 80 on the 50-item Wechsler 129 
Test of Adult Reading (W-TAR; as a surrogate measure of premorbid IQ); no other unstable 130 
medical or neuropsychiatric conditions (apart from AD or T2DM). All participants underwent 131 
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equivalent testing, including a structured neurological exam, medical history review, formal 132 
neuropsychological testing, and an EEG visit. Participant characteristics (Supplementary Table 133 
S1), including age, education, and premorbid IQ, were compared across groups using one-way 134 
analyses of variance (ANOVAs) with Tukey’s Honestly Significant Difference (HSD) post hoc 135 
comparisons. MMSE scores were compared using a non-parametric Kruskal-Wallis test. Gender 136 
proportions were compared using Fisher’s Exact Test. As the AD group was significantly older, 137 
Age was added as a covariate to all subsequent between-group analyses. Additionally, to verify 138 
that the main results were not confounded by between-group age differences, we reran several 139 
of the primary analyses on a cohort of 17 age-matched participants per group (see 140 
Supplementary Material for more details).  141 
This and all subsequent analyses were performed in JMP Pro (v12.0, 142 
http://www.jmp.com) using a normal distribution and a two-tailed 95% confidence interval. 143 
 144 
Neuropsychological testing 145 
Neuropsychological testing was performed on a separate visit from the EEG recording 146 
by a trained psychometrist. Tests and inventories were drawn from the National Alzheimer’s 147 
Coordination Center’s Uniform Data Set version 1.1 (NACC-UDS) (Beekly et al., 2007). The 148 
following neuropsychological tests were employed: the 15-item Geriatric Depression Scale 149 
(GDS); a 23-item Activities of Daily Living inventory (ADLs); the Digit Symbol Substitution Test 150 
(DSST; number of correct substitutions in 90 sec); Digit Span Forward and Backward tasks 151 
(longest set length repeated); the Logical Memory, Story-A (number of items recalled 152 
immediately and after a 30-minute delay without cueing) from the Wechsler Memory Scale-153 
Revised; the Trail Making Test (difference in time and in errors between parts B and A; TMTB-A) 154 
from the Halstead-Reitan Battery; the “animals” category of the Semantic Fluency Test (number 155 
of unique words generated in one min); and the 30-item Boston Naming Test (number of 156 
correctly named objects with semantic cue). In addition, the 70-item Cognitive subscale of the 157 
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Alzheimer’s disease Assessment Scale (ADAS-Cog) (Mohs et al., 1983) was administered to 158 
measure global cognitive function, and a 10-item version of the Rey Auditory Verbal Learning 159 
Test (RAVLT; percent correct during learning, 20-min delayed recall, and delayed recognition 160 
trials) (Rosenberg et al., 1984) was administered to further probe verbal learning and memory 161 
ability (Calero and Navarro, 2004). All measures were Z-transformed by subtracting the overall 162 
mean (across all three populations) of all subjects from each individual’s score and dividing it by 163 
the overall standard deviation in order to equalize the scale across measures, and facilitate data 164 
visualization and statistical analysis. Z-scores for the ADAS-Cog, GDS, and TMT were inverted 165 
so that in all measures, higher scores reflect better performance. To investigate the relationship 166 
between the EEG Spectral Power Ratio and cognitive function, three composite scores were 167 
computed by averaging together Z-scores of tests that tap into similar cognitive processes or 168 
measures: Dementia severity (ADAS-Cog, ADLs; measuring general cognitive functioning and 169 
functional independence), Executive functions (Digit Span forward and backward, TMTB-A 170 
Semantic fluency, DSST; measuring attention, working memory, set-shifting, strategic thinking 171 
and psychomotor processing speed); and Learning and memory (RAVLT, Logical Memory; 172 
measuring the acute ability to learn and recall verbal information with and without context). This 173 
approach—modelled after one from the Alzheimer’s Disease Neuroimaging Initiative (Crane et 174 
al., 2012; Gibbons et al., 2012) and used in a prior neuroimaging study (Buss et al., 2018)—175 
allowed oscillatory activity to be related to broad categories of cognitive processing rather than 176 
to specific tests. 177 
 178 
Electroencephalography acquisition and preprocessing 179 
Resting-state EEG was recorded using a 64-channel system (eXimia EEG, version 3.2, Nexstim 180 
Ltd, Finland) with a sampling rate of 1450Hz. EEG was acquired using an extended version of 181 
the “International 10-20 system” (Supplementary Figure S1 ). Ground and reference electrodes 182 
were placed on the forehead and two additional electrooculography electrodes (EOG) were 183 
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placed below and at the outer canthi of the left eye to identify vertical and horizontal eye 184 
movements. Impedances for all electrodes were kept below 5 kΩ. A 5-minute resting-state EEG 185 
recording was obtained while subjects sat in a semi-reclined armchair with their eyes closed. 186 
During recordings, the participants were instructed to remain quiet with their face muscles 187 
relaxed. The participant and EEG were monitored for signs of drowsiness at which point the 188 
participant was asked to blink their eyes a few times before closing them again. EEG data 189 
preprocessing was performed offline using a combination of the EEGLab toolbox (Delorme and 190 
Makeig, 2004a) and custom scripts in Matlab 2016a (Mathworks, USA). Data were filtered for 191 
line noise using a 55-65 Hz notch filter. Additional low-pass (100 Hz) and high-pass (1 Hz) filters 192 
were applied using a zero-phase second-order Butterworth filter. Filtered recordings were 193 
divided into 3-second epochs for visualization. Faulty or excessively noisy channels were 194 
visually detected and removed (average ±SD channels removed = 3.9 ±2.3; range = 0-9) and 195 
the remaining data were re-referenced to the average of all channels. After re-referencing, noisy 196 
epochs were identified semi-automatically and those containing excessive artifacts were 197 
rejected after visual inspection (average ±SD epochs removed = 25.9 ±20.5; range = 2-88), 198 
resulting in 48-116 usable epochs per participant with an average (±SD) of 86.9 (±14.0). 199 
Independent components analysis (ICA) was performed on cleaned data using fastICA 200 
(Rogasch et al., 2014), and components corresponding to blink/oculomotor, muscle or transient 201 
electrode artifacts were subtracted from the data. After component rejection, previously rejected 202 
channels were interpolated using a spherical spline interpolation and the data were down-203 
sampled to 1024Hz. 204 
 205 
Experimental design and Statistical Analysis 206 
Electroencephalography 207 
After EEG preprocessing, mean absolute power spectral density across epochs was calculated 208 
for each frequency band (1-40 Hz, 0.5 Hz resolution) at all electrodes using the spectopo 209 
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EEGlab function (window-size = 1024 samples, window-overlap = 512 samples) (Delorme and 210 
Makeig, 2004b). The power estimates for each frequency band were further divided by the sum 211 
of estimates across all frequencies in order to calculate the relative power of each frequency 212 
within the spectrum. To investigate group differences in EEG power, an analysis of covariance 213 
(ANCOVA) was performed at all electrode-frequency (1:40 Hz) points. The ANCOVA model 214 
included EEG power as the outcome measure, Diagnosis (HC, T2DM, AD) as a grouping 215 
variable, and Age as a continuous predictor to control for its effects on group differences in EEG 216 
power. Follow-up pairwise contrasts between groups were calculated using the Tukey-Kramer 217 
method. To control for the large number of multiple comparisons across electrode-frequency 218 
space, a non-parametric cluster based permutation approach was adopted (Maris and 219 
Oostenveld, 2007). Calculation of the test statistics involved the following: based on the initial 220 
ANCOVA’s and follow-up contrasts performed at all electrode-frequency points, data points 221 
corresponding to an uncorrected p-value < 0.05 were formed into clusters by grouping together 222 
adjacent significant electrode-frequency points. Note that for a sample to be included in a 223 
cluster it was required to have at least 1 neighboring significant sample in either frequency or 224 
space. The spatial neighborhood of each electrode was defined as all electrodes within 4 cm, 225 
resulting in a mean of 2.9 (min = 1, max = 4) and median of 3 neighbors per electrode. The F-226 
values (overall ANCOVA) or t-values (follow-up contrasts) within each identified cluster were 227 
summed to produce a cluster-level statistic. For the follow-up contrasts, the cluster-building 228 
procedure was performed separately for data points with positive and negative t-values (two-229 
tailed test). Subsequently, this cluster-building procedure was repeated across 2000 230 
permutations of the data. On each iteration, diagnostic group labels were randomly shuffled, 231 
thereby cutting the hypothesized relationship between diagnostic group and EEG power. The 232 
most extreme cluster-level F- or t-score was retrieved on each iteration to build data-driven null 233 
hypothesis distributions, separately for both the overall model and for each of the follow-up 234 
contrasts. The location of an original real cluster statistic within the null hypothesis distribution 235 
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indicates how probable such an observation would be if the null hypothesis were true (F-test: No 236 
difference in EEG power between any of the groups. Follow-up t-tests: No difference in EEG 237 
power between given two groups). For the overall model, if a given real cluster had a cluster-238 
statistic > 95% of the respective null distribution cluster-statistics, then this was considered a 239 
significant effect (5% α level). For the follow-up contrasts, if a given negative/positive cluster had 240 
a cluster-statistic lower/higher than 97.5% (2.5% α per tail) of the respective null distribution 241 
cluster-statistics, then this was considered a significant effect (5% total α level). This entire 242 
analysis was performed separately for both absolute and relative EEG power.  243 
 244 
EEG frequency bands and Spectral power ratio 245 
For subsequent analyses of EEG power, including its relationship with cognitive function, 246 
relative and absolute power estimates were extracted for each classical frequency band: δ (1-4 247 
Hz), θ (4-8 Hz), α (8-13 Hz), β (13-30 Hz), and gamma (γ; 30-40 Hz). Absolute power estimates 248 
were used to compute the Spectral Power Ratio, defined as the ratio of power in α and β to 249 
power in δ and θ: (α+β)/(δ+θ) (Supplementary Table S2 ). This approach has been utilized to 250 
assess alterations in the frequency distribution of EEG power, capturing in a single variable the 251 
pattern of a general shift in power from higher to lower frequencies that has been previously 252 
reported in AD (Babiloni et al., 2004; Bennys et al., 2001; Brenner et al., 1986; Coben et al., 253 
1983; Moretti et al., 2004). In order to assess the spatial distribution of the effects, the average 254 
of the relative power estimates for each frequency band and the average of the Spectral power 255 
ratio values were calculated separately for four cortical regions of interest (ROIs): Frontal 256 
(incorporating electrodes FP1, FPz, FP2, AF1, AFz, AF2, F5, F1, Fz, F2, F6), Central (FC5, 257 
FC3, FC1, FCz, FC2, FC4, FC6, C5, C3, C1, Cz, C2, C4, C6, CP5, CP3, CP1, CPz, CP2, CP4, 258 
CP6), Temporal (F7, F8, FT9, FT7, FT8, FT10, T3, T4, TP9, TP7, TP8, TP10), and Posterior 259 
(P9, P7, P3, P1, Pz, P2, P4, P8, P10, PO3, POz, PO4, O1, Oz, O2, Iz). 260 
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The relative power estimates from each of the four frequency bands plus the Spectral 261 
power ratio values were assessed independently via five mixed-effects linear regression 262 
analyses, each with a full-factorial model comprised of the between-subjects factor Group and 263 
the within-subject factor Cortical ROI (crossed with the random factor Subject to control for 264 
variance associated with repeated observations within the same individual), plus Age as a 265 
covariate (for details on the linear regression analysis of Spectral power ratio in the age-266 
matched subgroup cohort, see Supplementary materials). Each of the five analyses was 267 
followed by four fixed-effect linear regression analyses to test for group differences within each 268 
ROI separately. Significance values for these 20 follow-up analyses were adjusted for multiple 269 
comparisons using Holm-Bonferroni correction. Finally, post-hoc Tukey’s HSD tests were used 270 
to test for pairwise differences between groups.  271 
 272 
Analysis of neuropsychological performance and its relationships with Spectral power 273 
ratio 274 
Multivariate analyses of variance (MANOVAs) with a Wilk’s lambda (λ) distribution were used to 275 
compare neuropsychological performance across groups (MANOVA-1) and investigate its 276 
relationship with the Spectral power ratio across ROIs (MANOVA-2).  277 
MANOVA-1 was performed on Z-scores for the individual neuropsychological tests with 278 
the main factor of Group (HC, T2DM, AD), and Age as a covariate (for details on the MANOVA-279 
1 in the age-matched subgroup cohort, see Supplementary materials). Follow-up analyses 280 
consisted of separate linear regression models for each cognitive measure. Tukey’s HSD 281 
pairwise comparisons were performed for any regression model that survived a 5% false 282 
discovery rate (FDR) correction (Benjamini and Yekutieli, 2001). 283 
To investigate relationships between the Spectral power ratio and cognitive functions, 284 
MANOVA-2 was performed on the three composite scores with the factors Group, Cortical ROI 285 
and Spectral power ratio in a full-factorial model, plus Age as a covariate. Follow-up linear 286 
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regression analyses were performed for each domain (Learning and memory, Dementia 287 
severity, Executive functions), with the factors Group and Spectral power ratio in a full-factorial 288 
model with Age as a covariate (for details on the MANOVA-2 in the age-matched subgroup 289 
cohort, see Supplementary materials). As all effects that included the factor Cortical ROI were 290 
highly non-significant (see Results ), it was excluded from post-hoc analyses. For Learning and 291 
memory, the Group*Spectral power ratio interaction was highly non-significant (see Results ), so 292 
the model was rerun without that term. From these models, an overall correlation coefficient was 293 
calculated to express the relationship between the composite score and Spectral power ratio 294 
across all participants. Lastly, simple linear regression analyses were performed to assess the 295 
association of Spectral power ratio with each composite cognitive score in each group. 296 
Individual p-values for these 9 group-specific post-hoc analyses were adjusted for multiple 297 
comparisons with a 5% FDR.  298 
 299 
Individual α and posterior dominant frequencies 300 
During eyes-closed wakefulness, one of the most prominent features of the EEG signal is α-301 
band (~8-13Hz) activity, leading to the characteristic α peak in the power spectrum (Klimesch, 302 
2012; Keitel et al., 2019). We sought to investigate group differences in this dominant 303 
frequency, and whether these differences were related to cognitive function, using two 304 
independent metrics. First, in each participant we identified the individual frequency between 5-305 
15 Hz with the highest power density across all posterior electrodes using an automated peak-306 
finding algorithm based on smoothing of the 2nd order gradient of power spectral density (PSD) 307 
estimates with an 11-point, 3rd order polynomial Savitzky-Golay filter (Savitzky and Golay, 308 
1964; Corcoran et al., 2018; Keitel et al., 2018; Benwell et al., 2019). The posterior electrodes 309 
included in the analysis were P9, P7, P3, P1, Pz, P2, P4, P8, P10, PO3, POz, PO4, O1, Oz, O2 310 
and Iz. This approach incorporated a wider band of activity than the typical α range in order to 311 
capture potentially large shifts in the dominant frequency. Hence, we labelled this the Dominant 312 
 13
frequency analysis. In parallel, to look specifically at frequency and power changes within the 313 
classic α-range (8-12 Hz), two clinical neurophysiologists trained to interpret EEG (authors PDP 314 
and MMS) manually estimated the individual α frequency (IAF) for each participant using visibly-315 
identifiable alpha activity from the occipital and parieto-occipital electrodes. We labelled this the 316 
IAF analysis. For both the Dominant frequency and IAF analyses, we obtained both the peak 317 
frequency itself and the power density value averaged over the peak frequency ± 2.5 Hz. 318 
Hence, we were able to test simultaneously for group differences in both the peak frequency 319 
itself and the surrounding power density. These metrics were each entered into separate one-320 
way ANOVAs (with Age as a covariate) to investigate group differences and were also 321 
correlated with the cognitive composite scores.   322 
 323 
Results  324 
Participant characteristics 325 
By design, MMSE scores were lower in the AD group relative to both T2DM and HC. AD 326 
participants were also significantly older than HC, but not T2DM. The groups were equivalent in 327 
years of education, pre-morbid IQ, and proportions of men and women (for full details on 328 
participant characteristics across groups, see Supplementary Table S1 ). 329 
 330 
EEG Power 331 
The following details the results of the primary analysis of relative EEG power. For equivalent 332 
analyses of absolute EEG power and their results, see Supplementary Materials Section 1 333 
(including Table S2  and Figure S2 ).  334 
 335 
A main effect of Group, controlling for age, was identified in the δ+θ frequency bands (~1–7 Hz) 336 
and also in the α+β (~8.5–21 Hz) and low–γ bands (30–40 Hz, Figure 1A-B ). Relative δ+θ 337 
power were higher for AD compared to T2DM and HC, whereas relative α+β power were lower 338 
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for AD compared to T2DM and HC (Figure 1C ). Pairwise contrasts (Figure 1D-F ) demonstrated 339 
higher relative δ+θ power in AD than both HC and T2DM, and lower relative α+β power in AD 340 
compared to either HC or T2DM. Additionally, there was significantly higher relative power in the 341 
low–γ band in AD compared to HC. No clusters survived correction for the T2DM-HC contrast.  342 
 343 
 344 
Figure 1. Whole-brain analysis of relative power. A. F-ratios associated with between-group mass univariate 345 
analyses of variance (ANOVAs) comparing relative electroencephalography (EEG) power between Alzheimer’s 346 
disease (AD), Type-2 diabetes mellitus (T2DM), and healthy controls (HC) across all electrodes (y-axis) and 347 
frequencies (x-axis). The solid black contour represents data points surviving cluster-based multiple comparison 348 
correction. B. Topographic representation of the F-ratios averaged across the significant frequencies. C. Mean power 349 
spectra (with 95% confidence intervals) for each group separately at the electrode (CP6) for which group differences 350 
were maximal. Alpha/beta power showed a linear decrease across groups, being highest for HC and lowest for AD 351 
with T2DM having intermediate values whereas delta/theta power showed a linear increase across groups. D-F. T-352 
values associated with follow-up tests comparing relative EEG power between each pair of groups separately. Solid 353 
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black contours indicate data points surviving cluster-correction. G-H. Topographic representation of the t-values 354 
associated with the respective significant effects. Significant electrodes are highlighted in gray. 355 
 356 
Classic EEG frequency bands across ROIs 357 
Delta: There were significant main effects of Group (F2,68 = 8.7, p < .001) and Cortical ROI (F3,207 358 
= 59.1, p < .001), but no Group*Cortical ROI interaction (F6,207 = 1.2, p = .292). Follow-up tests 359 
showed a similar pattern of group differences across the four Cortical ROIs (p values < .015, 360 
adjusted), with AD showing greater relative δ power than both HC and T2DM (p values < .05). 361 
 362 
Theta: There were significant main effects of Group (F2,68 = 12.7, p < .001) and Cortical ROI 363 
(F3,207 = 3.3, p = .023), but no Group*Cortical ROI interaction (F6,207 = 2.1, p = .060). Follow-up 364 
tests showed a similar pattern of group differences across the four ROIs (p values < .004, 365 
adjusted), with AD showing greater relative θ power than both HC and T2DM (p values < .05). 366 
 367 
Alpha: There were significant main effects of Group (F2,68 = 9.9, p < .001) and Cortical ROI 368 
(F3,207 = 61.7, p < .001), as well as a Group*Cortical ROI interaction (F6,207 = 4.9, p < .001). 369 
Follow-up tests showed somewhat different pattern of group differences across the four ROIs (p 370 
values < .013, adjusted). Relative α power was lower in AD than HC across all ROIs. Relative α 371 
power was also lower in AD than in T2DM in the Frontal, Temporal, and Posterior (but not 372 
Central) ROIs. T2DM had significantly lower α power than HC in the Temporal ROI only (all p 373 
values < .05).  374 
 375 
Beta: There was a significant main effect of Cortical ROI (F3,207 = 47.5, p < .001), while Group 376 
(F2,68 = 1.1, p = .337) and Group*Cortical ROI were not significant (F6,207 = 1.8, p = .094). 377 
Follow-up tests showed a similar pattern of equivalent β power across groups, regardless of the 378 
ROI (p values > .7, adjusted). 379 
 380 
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Spectral power ratio: There were significant main effects of Group (F2,68 = 9.2, p < .001) and 381 
Cortical ROI (F3,207 = 20.8, p < .001), as well as a Group*Cortical ROI interaction (F6,207 = 3.3, p 382 
= .004). Follow-up analyses showed a pattern of group differences in Posterior ROI (HC > AD; p 383 
= .012, adjusted) that was distinct from the other ROIs (HC, T2DM > AD; p values < .008, 384 
adjusted) (Figure 2 ). These results indicate a shift of power from higher frequencies to lower 385 
frequencies in AD and suggest a similar pattern may be emerging in T2DM. Of note, an 386 
equivalent analysis in the age-matched sub-cohort demonstrated essentially identical findings 387 
(see Supplementary materials Section 2).   388 
 389 
 390 
Figure 2. Spectral power ratio. Figure shows the age-adjusted comparison across groups of the Spectral Power 391 
Ratio (α+β)/(δ+θ) estimated from each cortical region of interest (ROI). Tukey’s Honestly Significant Difference post-392 
hoc tests demonstrated that (α+β)/(δ+θ) was lower in Alzheimer’s disease (AD) than in Healthy Controls (HC) across 393 
all ROIs (p values < 0.001) and lower than Type-2 Diabetes (T2DM) in all but the Posterior ROI (p values = 0.0499 – 394 
0.063). T2DM was lower than HC across all ROIs though this difference did not reach significance (p values = 0.064 395 
– 0.136). Data shown represent the least squared means and standard deviations derived from the linear regression 396 
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Neuropsychological function and relationship to EEG spectral power 399 
Group averaged neuropsychological test scores (z-scored) are displayed in Figure 3 .  400 
 401 
 402 
Figure 3. Group analysis and post-hoc comparisons of cognitive measures adjusted for age. All data represent least 403 
squared means and standard error. Individual neuropsychological tests (x-axis) are shown grouped by cognitive 404 
domain. Scores (y-axis) were z-normalized and inverted (if necessary) so higher numbers reflect better 405 
performance/function. Following the first omnibus multivariate analysis of variance (MANOVA-1), group performance 406 
on individual tests was assessed using separate multiple linear regression analyses with age as a covariate. All 407 
results survived a 5% false discovery rate (FDR). In general there was a continuum of deficits with healthy controls 408 
(HC) scoring higher than Type-2 diabetics (T2DM), who performed better than Alzheimer’s disease (AD). Post-hoc 409 
pairwise comparisons were conducted with Tukey’s honestly significant difference (HSD) tests. Three patterns were 410 
observed: (§) all three groups were significantly different; (†) AD scored significantly worse than both HC and T2DM, 411 
which were equivalent to each other; (^) HC were significantly better than AD, with T2DM not significantly different 412 
from either group. Additional abbreviations. Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog); 413 
Activities of Daily Living (ADLs); Digit Symbol Substitution Test (DSST); Trail Making Test (TMT); Rey Auditory 414 
Verbal Learning Test (RAVLT); Geriatric Depression Scale (GDS). 415 
 416 
MANOVA-1 (Table 1 ) demonstrated that the variance in cognitive scores was different 417 
between the groups after controlling for Age, F(30, 86)=6.7, η
2
p=0.70, p<0.001, while Age itself 418 
was not a predictor of cognitive function, F(15,43)=1.7, η
2
p=0.37, p=0.096. Follow-up linear 419 
regression analyses yielded significant variance by Group for each neuropsychological measure 420 
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after controlling for Age (F’s>5.7, p’s<0.006: see Supplementary Table S3 ). All measures 421 
survived a 5% FDR correction. For equivalent analyses in the age-matched sub-cohort with 422 
similar findings, see Supplementary materials Section 2.  423 
 424 
Table 1. Results of Multivariate Analyses of Variance (MANOVAs).  
 MANOVA-1 
 Factor Wilks' λ df F ratio P value Partial Eta
2
 
Group 0.090 30,86 6.670 <.001 0.699 
Age 0.581 15,43 1.666 0.0958 0.368 
 MANOVA-2 
 Factor Wilks' λ df F ratio P value Partial Eta
2
 
Group 0.550 6,522 30.200 <.001 0.260 
Spectral Power Ratio 0.399 3,261 36.100 <.001 0.290 
Group*Spectral Power Ratio 0.532 6,522 29.100 <.001 0.250 
Age 0.215 3,261 6.200 <.001 0.070 
 425 
In MANOVA-1, the dependent variables included z-normalized, rectified scores on the Alzheimer's disease 426 
Assessment Scale-Cognitive Subscale, Activities of Daily Living, Digit Symbol Substitution Test, Semantic Fluency 427 
Test, Trail Making Test time and errors (difference Part B-Part A), Digit Span length forward and backward, Rey 428 
Auditory Verbal Learning Test (learning, delayed recall, delayed recognition), Logical Memory story (immediate and 429 
delayed recall), Boston Naming Test, and Geriatric Depression Scale. In MANOVA-2, the dependent variables 430 
include the averaged Z-scores of the three cognitive domains (Learning & memory, Dementia severity, Executive 431 
function). Spectral Power Ratio refers to a whole-brain averaged power ratio [(alpha + beta)/(delta + theta)] obtained 432 
from eyes-closed resting-state electroencephalography. 433 
 434 
Following Tukey’s HSD comparisons, two major patterns emerged (Figure 3 ): For 435 
scores on the DSST, RAVLT learning and delayed recognition trials, Logical Memory immediate 436 
and delayed recall trials, there were significant differences between all three groups with AD < 437 
T2DM < HC (p’s<0.03). By comparison, on the ADAS-Cog, ADLs, Semantic fluency, TMT time, 438 
TMT errors, Digit Span backward, RAVLT delayed recall, Boston Naming Test, and GDS, the 439 
AD group performed worse than either the HC or T2DM groups (p’s<0.04), while the latter two 440 
groups did not differ from each other (p’s>0.2). Lastly, on the Digit Span forward test was there 441 
a difference only between HC and AD (p=0.004) with T2DM not different from either HC or AD 442 
(p>0.1).  443 
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Concerning the association of cognitive function with the Spectral power ratio, 444 
MANOVA-2 (Table 1 ) indicated a main effect of Group, Wilks’ λ=0.55, F(6,522)=30.2, η
2
p=0.26, 445 
p<0.001, and an overall relationship between the composite neuropsychological scores and the 446 
Spectral power ratio, F(3,261)=36.1, η
2
p=0.29, p<0.001. In addition, there was a Group*Spectral 447 
power ratio interaction, F(6,522)=29.1, η
2
p=0.25, p<0.001, indicating that the overall relationship 448 
between cognition function and (α+β)/(δ+θ) differed between groups. Importantly, none of the 449 
effects that included Cortical ROI as a factor were significant (F ratios < .7, p values > .78), 450 
indicating that the overall relationship between the (α+β)/(δ+θ) and cognitive function did not 451 
vary as a function of cortical region. In contrast to MANOVA-1, Age was a predictor of cognitive 452 
function after controlling for Group, Cortical ROI, and Spectral power ratio, F(3,261)=6.2, p<.001. 453 
Post-hoc linear regression analyses showed that across all participants, Spectral power ratio 454 
had significant positive associations with Learning and memory (R67=0.27, p=0.040), Dementia 455 
severity (R65=0.44, p<0.001), and Executive functions (R65=0.43, p<0.001) (Figure 4 ); partial 456 
correlation coefficients were calculated from a model that included Group, Age, and the 457 
Group*Spectral power ratio interaction (except Learning and memory, for which the interaction 458 
term was highly non-significant, p=0.954). 459 
Considering cognition-EEG relationships within each group separately, higher Spectral 460 
power ratio was associated with better Learning and memory performance in HC (Figure 4A ; 461 
p=0.018, uncorrected). In AD, higher (α+β)/(δ+θ) was associated with lower Dementia severity 462 
(Figure 4B ) and better Executive function performance (Figure 4C ), p’s<0.05, uncorrected). In 463 
contrast to HC and AD, no significant relationships were observed for T2DM (p’s>0.1). After 464 
subjecting p-values to a 5% FDR, the relationship between Spectral power ratio and Executive 465 




Figure 4. Relationship between electroencephalography (EEG) Spectral Power Ratio and cognitive function. Z-469 
normalized scores (higher score indicates better performance) from individual neuropsychological tests were 470 
averaged together to form three domains: A. Learning & memory (Rey Auditory Verbal Learning Test, Logical 471 
Memory Story); B. Dementia severity (Alzheimer’s disease Assessment Scale-Cognitive subscale, Activities of Daily 472 
Living); C. Executive function (Digit Symbol Substitution Test, Semantic fluency, Trail Making, Digit Span forward and 473 
backward). Computed averages were related to the EEG Spectral Power Ratio (α+β)/(δ+θ) and plotted separately for 474 
the three groups. In healthy controls (HC), higher (α+β)/(δ+θ) was significantly associated with better Learning & 475 
memory performance (p = 0.018, uncorrected). In Alzheimer’s disease (AD), higher (α+β)/(δ+θ) was significantly 476 
associated with better Dementia severity and Executive function (p’s < 0.05, uncorrected). By contrast, no significant 477 
relationships were observed in the Type-2 diabetes mellitus (T2DM) group (p’s > 0.1).  478 
 479 
 480 
Individual alpha and posterior dominant frequencies 481 
Dominant frequency (see Figure 5A ): A main effect of Group, controlling for Age, was identified 482 
(F(2,68) = 6.26, η
2
p = 0.22, p = 0.001). The Dominant frequency was significantly lower in AD 483 
(mean = 8.2 Hz) compared to both T2DM (9.4 Hz: p = 0.002) and HC (9.3 Hz: p = 0.003). There 484 
was no significant difference between T2DM and HC (p = 0.99).  485 
 486 
Power density at dominant frequency (see Figure 5B ): A main effect of Group was identified 487 
(F(2,68) = 3.41, η
2
p = 0.09, p = 0.039). Power density in the Dominant frequency band was 488 
significantly lower in AD compared to HC (p = 0.05) but not compared to T2DM (p = 0.47). 489 
There was no significant difference between T2DM and HC (p = 0.08). 490 
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491 
Figure 5. Group analysis of posterior dominant frequencies. A. Individual frequency between 5-15 Hz with the 492 
highest power density across all posterior electrodes (posterior dominant frequency) as a function of group (Healthy 493 
controls (HC), Type-2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD)). B. Power density at the posterior 494 
dominant frequency (averaged over the peak frequency ± 2 Hz) as a function of group. Colored dots denote individual 495 
participants, white dots denote group medians and background fills represent kernel density estimates. 496 
 497 
Similar results were found for the IAF analysis (see supplementary Section 3 and Figure 498 
S3). Hence, there was a shift of the dominant rhythm towards lower frequencies in AD relative 499 
to both T2DM and healthy controls. However there is also a reduction in power at both the 500 
Dominant frequency and the IAF in AD. Intriguingly, T2DM showed significantly higher 501 
Dominant frequency and IAF values compared to AD (in line with HC), but did not show any 502 
significant difference in terms of power density at either the Dominant frequency or the IAF (in 503 
contrast to HC). This suggests that, unlike in AD, the frequency of the dominant posterior 504 
rhythm in T2DM is indistinguishable to that observed in HC. However, in terms of power density 505 
at the dominant rhythm, T2DM resembled AD more closely than HC. 506 
In contrast to the Spectral power ratio, there was no significant relationship between any 507 
of the composite cognitive measures and either the Dominant Frequency or IAF.        508 
 509 
Discussion  510 
The present study compared oscillatory power and neuropsychological function (and their 511 
relationship) between HC, AD and T2DM in order to better understand pathophysiological 512 
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signatures of cognitive aging. Cognitively, AD was associated with deficits across almost all 513 
neuropsychological tests, whereas T2DM was associated with selective deficits in 514 
verbal/episodic learning, memory and psychomotor processing speed. Neurophysiologically, 515 
there was a pattern of shifting EEG power from higher to lower frequencies in AD, and evidence 516 
that a similar shift is also apparent to a lesser degree in T2DM, particularly over temporal 517 
regions. Capturing this shift as a single measure (the ratio of α+β/δ+θ power) across 518 
participants allowed us to investigate the relevance of these oscillatory changes for cognitive 519 
aging. This Spectral power ratio was uniquely associated with executive functions and dementia 520 
severity in the AD group, and with learning and memory function in the HC group. The results 521 
suggest that a shift in EEG power from higher to lower frequencies represents a candidate 522 
biomarker for specific cognitive deficits associated with aging and brain-related diseases.  523 
  524 
Some of the results replicate findings from previous studies which, particularly given recent 525 
concerns about the reproducibility of scientific findings in both neuroimaging (Poldrack et al., 526 
2017) and psychology (Open Science Collaboration, 2015), is of great importance in 527 
establishing the reliability of the reported effects. Moreover, the current findings go beyond 528 
replication to extend prior work by collapsing the spectral power distribution into a single easily 529 
obtainable summary metric, and then examining how this metric relates to specific domains of 530 
cognitive function. We contribute several important novel insights into the pathophysiology of 531 
cerebral oscillations in AD and T2DM relative to normal cognitive aging. The novel aspects 532 
include (1) a direct comparison of EEG activity and neuropsychological performance between 533 
AD, T2DM and healthy controls, (2) extensive testing of group differences in both absolute and 534 
relative EEG power across all electrodes and a wide range of frequencies (1-40 Hz), (3) a 535 
parsing of the relationship between oscillatory abnormalities and specific cognitive domains (i.e. 536 
memory versus executive function) across the different groups, (4) evaluation of the distribution 537 
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of frequency changes across different brain regions, and (5) analyses of shifts in the Dominant 538 
frequency, as well as in the power density at this individually-defined dominant frequency.      539 
 540 
Differences in cognitive function associated with AD and T2DM 541 
AD participants showed marked neuropsychological deficits relative to both HC and T2DM. The 542 
most prominent deficits were observed on learning, memory and executive function tests. AD 543 
participants also reported impaired function in activities of daily living and increased symptoms 544 
of depression compared to both HC and T2DM. These symptoms are well established in AD 545 
(Burns and Iliffe, 2009).  546 
Additionally, a pattern of performance differences was observed from HC to T2DM to AD 547 
on verbal/episodic learning (RAVLT and Logical Memory) and psychomotor processing speed 548 
(DSST). These findings accord with previous reports of mild decrements in memory, motor 549 
function and attention and perceptual processing speed in T2DM relative to HC (Cheng et al., 550 
2012; Marseglia et al., 2016; Mooradian et al., 1988; Palta et al., 2014; Takeuchi et al., 2012; 551 
van den Berg et al., 2010). Thus, T2DM may affect these cognitive domains first, and the effects 552 
are detectable using commonly employed neuropsychological tests. It is important to 553 
acknowledge that cognitive impairment in T2DM is likely modulated by many variables, 554 
including vascular risk factors (Marseglia et al., 2016), presence of the apolipoprotein ε4 allele 555 
(Ravona-Springer et al., 2014) and glycemic control (Yaffe et al., 2012). These factors were not 556 
controlled for here, and may have contributed to the observed cognitive deficits. However, the 557 
current results provide evidence that mild neuropsychological deficits are detectable in T2DM 558 
even when participants report no cognitive impairment.         559 
 560 
Changes in oscillatory activity and relationship with cognition in AD 561 
The present study suggests that both AD and T2DM are associated with abnormal neural 562 
oscillations, relative to HC. In AD, we observed reduction in α+β power and increase in δ+θ 563 
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power, in line with previous findings (Babiloni et al., 2016; Bennys et al., 2001; Brenner et al., 564 
1986; Coben et al., 1990, 1983; Dierks et al., 1995; Fraga et al., 2013; Jeong, 2004; Moretti et 565 
al., 2004; Neto et al., 2016). There was a similar pattern of higher δ+θ power (HC < AD), and a 566 
similar pattern of lower α+β power (HC > AD), across all ROIs. These oscillatory signatures, as 567 
captured by the ratio of (α+β)/(δ+θ) power, correlated with learning and memory function across 568 
all groups combined, though the correlation was relatively weak within each group and only 569 
significant in HC. In AD, the Spectral power ratio was strongly associated with executive 570 
function performance and dementia severity, with the degree of change being positively 571 
correlated with symptom severity. Previous studies have found a correlation between band-572 
specific EEG power and the severity of cognitive deficits in AD (Babiloni et al., 2007, 2006a; 573 
Dierks et al., 1995; Helkala et al., 1991; Luckhaus et al., 2008; Moretti et al., 2009; van der Hiele 574 
et al., 2007). The current results confirm and expand on this literature, suggesting that the ratio 575 
of (α+β)/(δ+θ) power is a strong predictor specifically of executive function in AD (accounting for 576 
more than 55% of the variance). Notably, the Spectral power ratio was also associated with 577 
overall dementia severity, suggesting that deficits in executive functions (as opposed to learning 578 
and memory) may be more closely tied to global indicators of dementia. Intriguingly, similar 579 
neural changes are predictive of progression from MCI to dementia (Babiloni et al., 2011; 580 
Grunwald et al., 2001; Jelic et al., 2000, 1996; Rossini et al., 2006) and have been associated 581 
with cognitive deficits in disorders such as ADHD (Barry et al., 2003), dyslexia (Penolazzi et al., 582 
2008), schizophrenia (Bates et al., 2009; Boutros et al., 2008) and Parkinson’s disease (Klassen 583 
et al., 2011; Olde Dubbelink et al., 2014).  584 
In line with previous studies (Moretti et al., 2004; Poza et al., 2007; Babiloni et al., 2015), 585 
we found lower dominant posterior frequencies in AD (mean = 8.2 Hz) relative to both HC and 586 
T2DM, who showed typical mean dominant frequencies in the α-band (Klimesch, 1999; Mierau 587 
et al., 2017; Knyazeva et al., 2018). However, in contrast to the Spectral power ratio, we found 588 
no relationship between the posterior dominant frequency or IAF and performance on any of the 589 
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composite cognitive scores. This suggests that pathophysiological changes in power density in 590 
AD are more cognitively relevant than changes in peak frequency.  591 
 592 
Changes in oscillatory activity and relationship with cognition in T2DM  593 
Interestingly, α+β power density in T2DM participants was intermediate between HC and AD 594 
participants. This finding replicates and extends the results of Cooray et al. (2011), who found 595 
that α+β power was reduced in T2DM compared to HC. We also found that T2DM is specifically 596 
associated with a reduction of α power in the temporal regions, with no significant differences 597 
observed in other brain regions relative to HC. This is notable insofar as deficits in temporal α 598 
power have previously been linked to impairments in learning and memory in AD (Babiloni et al., 599 
2009). Interestingly, a subset of T2DM participants in the study of Cooray et al. (2011) who 600 
received a 2-month glycemic control treatment showed an increase in α power, associated with 601 
improvements in visuospatial and semantic memory performance. Collectively, these results 602 
highlight alterations in brain function and α power associated with T2DM (Fried et al., 2017; 603 
Strachan et al., 2011).  604 
No difference was found between T2DM and HC in either the Dominant posterior 605 
frequency or the IAF. However, despite the peak frequency remaining intact, a tendency was 606 
observed for a reduction in power density at both the Dominant posterior frequency and the IAF, 607 
with the power density profile in T2DM more closely resembling AD than HC. To our knowledge, 608 
this represents the first analysis of peak frequencies in T2DM. Though we found no link 609 
between these power density changes and neuropsychological performance in the current 610 
sample, future longitudinal studies may investigate further whether they are cognitively relevant 611 
and potentially prodromal of later changes in peak frequency. 612 
 613 
Differences in cognitive relevance of oscillatory signatures between AD and T2DM 614 
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Though T2DM confers an increased risk for developing AD (Biessels and Kappelle, 2005; 615 
Barbagallo and Dominguez, 2014), little is known about the mechanistic underpinnings that link 616 
the two disorders (Chatterjee and Mudher, 2018; Chornenkyy et al., 2019). In contrast to AD, we 617 
found no correlation between the Spectral Power Ratio and the degree of cognitive impairment 618 
in T2DM for any of the neuropsychological tests in our battery. It is possible that this highlights 619 
the domain-specific nature of the EEG–cognition link, as the T2DM group showed no marked 620 
deficits on the executive function tests, which were most strongly related to the Spectral Power 621 
Ratio in AD. A related possibility concerns the multifactorial nature of T2DM-related impact on 622 
the brain. Despite some similarities in the observed EEG changes associated with AD and 623 
T2DM, the electrophysiological signatures linked to cognitive deficits may not be the same due 624 
to differing neurodegeneration and cerebrovascular pathologies. This proposal could be tested 625 
in future studies by combing resting-state EEG recordings and comprehensive 626 
neuropsychological testing with structural magnetic resonance imaging (MRI) in both AD and 627 
T2DM samples. This may allow for the establishment of a physiological link between oscillatory 628 
activity, structural abnormalities and cognitive functions. Such an approach would shed further 629 
light on similarities and differences in the neuropathological processes underlying cognitive 630 
impairment in T2DM and AD. 631 
 632 
EEG oscillations and cognition 633 
Oscillatory EEG activity reliably co-varies with cognitive functions in a band- and domain-634 
specific manner (Basar et al., 2001). For example, α-band activity has been associated with 635 
memory (Bonnefond and Jensen, 2012; Klimesch, 1999; Palva and Palva, 2007), attention 636 
(Benwell et al., 2017, 2018; Foxe and Snyder, 2011), and arousal (Benwell et al., 2018; Cantero 637 
et al., 1999; Sadaghiani et al., 2010), while β-activity is believed to play a role in sensorimotor 638 
functions (Pfurtscheller et al., 1996) and the maintenance of top-down attention (Buschman and 639 
Miller, 2007; Engel and Fries, 2010). These findings have led to suggestions that oscillations are 640 
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computationally relevant for neuronal synchrony/communication and higher-order cognition 641 
(Canolty and Knight, 2010).  642 
Hence, changes in EEG power associated with pathophysiology may reflect abnormal 643 
synchronization of large-scale networks of pyramidal cortical neurons and consequent 644 
impairment of information transfer required for cognitive functions. Recent studies employing 645 
both structural neuroimaging and EEG/MEG suggest that increases in δ+θ power (and 646 
reductions in α power) correlate with neurodegenerative processes associated with AD such as 647 
atrophy of sub-cortical white matter, cortical gray matter and hippocampus (Babiloni et al., 2013, 648 
2006b; Fernandez et al., 2003; Helkala et al., 1996).  649 
From a functional perspective, one theory linking frequency ratio changes with cognitive 650 
impairment suggests a possible reciprocal relationship between α-band and low-frequency 651 
(δ+θ) activity (Knyazev, 2012, 2007). Specifically, α-activity is implicated in controlling adaptive 652 
functional inhibition (Klimesch et al., 2007), facilitating goal-directed sensory and behavioral 653 
regulation. Accordingly, when this reciprocal relationship is unbalanced, through reductions in α-654 
mediated inhibition and/or abnormal increases in low-frequency activity, pathological 655 
disinhibition occurs with consequent cognitive and behavioral impairments (Knyazev, 2012, 656 
2007). Notably, differences in the spectral ratio between T2DM and HC were primarily driven by 657 
reduced power in higher (α+β) frequencies in T2DM, without a strong increase in low-frequency 658 
(δ+θ) power. If reduction in α-power indexes decreased functional inhibition relevant for 659 
cognitive performance, then this may be prodromal in T2DM of subsequent increase in low-660 
frequency activity and accelerated cognitive decline. Unfortunately, due to the single time-661 
point/cross-sectional nature of the current study, the results cannot provide evidence as to the 662 
existence of any causal link between T2DM and AD. It is crucial to acknowledge that the causal 663 
factors underlying cognitive impairments may not be shared across the disorders; hence, we 664 
cannot yet ascribe the EEG differences to a single underlying cause. Future longitudinal, 665 
prospective studies are however warranted given existing epidemiologic data and the reported 666 
 28
cross-sectional findings here. Longitudinal measurements of EEG power and 667 
neuropsychological performance in individuals with T2DM could test the prognostic power of 668 
EEG changes in terms of subsequent cognitive decline, including progression to AD (Gispen 669 
and Biessels, 2000; Stewart and Liolitsa, 1999).  670 
Additional limitations of the current study include a lack of older participants, particularly 671 
in the T2DM and HC groups. Future studies should look to recruit from a wider range of older 672 
adults. It is important to note that, despite no individuals scoring as clinically impaired on the 673 
MMSE, we were unable to fully rule out the possibility of pre-clinical AD being present in the HC 674 
and T2DM groups. It would also be of benefit to collect more potentially relevant demographic 675 
details which were not available here, including smoking status, comorbid psychiatric 676 
symptomology and time since diagnosis. Additional information regarding medication use might 677 
be of particular value given that T2DM treated with medications may not experience equivalent 678 
neurocognitive consequences to those controlling the disease through exercise and diet (Walker 679 
and Harrison, 2015; Ngandu et al., 2015). Furthermore, we did not consider the potential 680 
association between γ-band (~30-100 Hz) oscillations and cognitive function in either T2DM or 681 
AD, despite previous research suggesting γ-band activity to be cognitively relevant (van 682 
Deursen et al., 2008; Başar et al., 2016). We chose not to include EEG-measured γ because it 683 
is often contaminated by muscle (Whitham et al., 2007) and eye-movement artifacts (Yuval-684 
Greenberg et al., 2008). An optimal approach to investigate pathophysiological signatures of γ 685 
activity in future studies would be to employ magnetoencephalography, in which cerebral γ 686 
activity can be more clearly and robustly identified than in EEG (Mandal et al., 2018). 687 
 688 
Conclusions 689 
Neuropsychological deficits are widespread in AD and selective in T2DM (with relative sparing 690 
of executive functions). Relative to HC, AD patients had higher EEG power in lower frequencies 691 
and lower power in higher frequencies across all brain regions. In contrast, patients with T2DM 692 
 29
showed decreases in specifically α power relative to HC restricted to the temporal regions. The 693 
ratio, (α+β)/(δ+θ), showed a continuum of differences from HC to T2DM to AD. This Spectral 694 
power ratio correlated with dementia severity and executive functioning in AD and learning and 695 
memory performance in HC and across all groups combined. In contrast, no relationship was 696 
found between IAF and cognitive function in any of the three groups. Shift in the ratio of relative 697 
power (in favor of low frequencies) within the EEG power-spectrum represents a candidate 698 
neural signature of cognitive deficits associated with aging-related diseases including AD and 699 
T2DM.  700 
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Figure Legends 1220 
Figure 1. Whole-brain analysis of relative power. A. F-ratios associated with between-group 1221 
mass univariate analyses of variance (ANOVAs) comparing relative electroencephalography 1222 
(EEG) power between Alzheimer’s disease (AD), Type-2 diabetes mellitus (T2DM), and healthy 1223 
controls (HC) across all electrodes (y-axis) and frequencies (x-axis). The solid black contour 1224 
represents data points surviving cluster-based multiple comparison correction. B. Topographic 1225 
representation of the F-ratios averaged across the significant frequencies. C. Mean power 1226 
spectra (with 95% confidence intervals; CI) for each group separately at the electrode (CP6) for 1227 
which group differences were maximal. Alpha/beta power showed a linear decrease across 1228 
groups, being highest for HC and lowest for AD with T2DM having intermediate values whereas 1229 
delta/theta power showed a linear increase across groups. D-F. T-values associated with follow-1230 
up tests comparing relative EEG power between each pair of groups separately. Solid black 1231 
contours indicate data points surviving cluster-correction. G-H. Topographic representation of 1232 
the t-values associated with the respective significant effects. Significant electrodes are 1233 
highlighted in gray.  1234 
 1235 
Figure 2. Spectral Power Ratio. Figure shows the age-adjusted comparison across groups of 1236 
the Spectral Power Ratio, (α+β)/(δ+θ), estimated from each cortical region of interest (ROI). 1237 
Tukey’s Honestly Significant Difference post hoc tests demonstrated that (α+β)/(δ+θ) was lower 1238 
in Alzheimer’s disease (AD) than in Healthy Controls (HC) across all ROIs (p values < 0.001) 1239 
and lower than Type-2 Diabetes (T2DM) in all but the Posterior ROI (p values = 0.0499–0.063). 1240 
T2DM was lower than HC across all ROIs though this difference did not reach significance (p 1241 
values = 0.064–0.136). Data shown represent the least squared means and standard deviations 1242 
derived from the linear regression models.  1243 
 1244 
 42
Figure 3. Group analysis and post-hoc comparisons of cognitive measures adjusted for age. All 1245 
data represent least squared means and standard error. Individual neuropsychological tests (x-1246 
axis) are shown grouped by cognitive domain. Scores (y-axis) were z-normalized and inverted 1247 
(if necessary) so higher numbers reflect better performance/function. Following the first omnibus 1248 
multivariate analysis of variance (MANOVA-1), group performance on individual tests was 1249 
assessed using separate multiple linear regression analyses with age as a covariate. All results 1250 
survived a 5% false discovery rate (FDR). In general, there was a continuum of deficits with 1251 
healthy controls (HC) scoring higher than Type-2 diabetics (T2DM), who performed better than 1252 
Alzheimer’s disease (AD). Post-hoc pairwise comparisons were conducted with Tukey’s 1253 
honestly significant difference (HSD) tests. Three patterns were observed: (§) all three groups 1254 
were significantly different; (†) AD scored significantly worse than both HC and T2DM, which 1255 
were equivalent to each other; (^) HC were significantly better than AD, with T2DM not 1256 
significantly different from either group. Additional abbreviations. Alzheimer’s disease 1257 
Assessment Scale-Cognitive subscale (ADAS-Cog); Activities of Daily Living (ADLs); Digit 1258 
Symbol Substitution Test (DSST); Trail Making Test (TMT); Rey Auditory Verbal Learning Test 1259 
(RAVLT); Geriatric Depression Scale (GDS). 1260 
 1261 
Figure 4. Relationship between electroencephalography (EEG) Spectral power ratio and 1262 
cognitive function. Z-normalized scores (higher score indicates better performance) from 1263 
individual neuropsychological tests were averaged together to form three domains: A. Learning 1264 
& memory (Rey Auditory Verbal Learning Test, Logical Memory Story); B. Dementia severity 1265 
(Alzheimer’s disease Assessment Scale-Cognitive subscale, Activities of Daily Living); C. 1266 
Executive function (Digit Symbol Substitution Test, Semantic fluency, Trail Making, Digit Span 1267 
forward and backward). Computed averages were related to the Spectral Power Ratio 1268 
(α+β)/(δ+θ) and plotted separately for the three groups. In healthy controls (HC), higher 1269 
(α+β)/(δ+θ) was significantly associated with better Learning & memory performance (p = 0.018, 1270 
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uncorrected). In Alzheimer’s disease (AD), higher (α+β)/(δ+θ) was significantly associated with 1271 
better Dementia severity and Executive function (p’s < 0.05, uncorrected). By contrast, no 1272 
significant relationships were observed in the Type-2 diabetes mellitus (T2DM) group (p’s > 1273 
0.1).  1274 
 1275 
Figure 5. Group analysis of Dominant posterior frequencies. A. Individual frequency between 5-1276 
15 Hz with the highest power density across all posterior electrodes (Dominant posterior 1277 
frequency) as a function of group (Healthy controls (HC), Type-2 diabetes mellitus (T2DM) and 1278 
Alzheimer’s disease (AD)). B. Power density at the Dominant posterior frequency (averaged 1279 
over the peak frequency ± 2 Hz) as a function of group. Colored dots denote individual 1280 
participants, white dots denote group medians and background fills represent kernel density 1281 
estimates. 1282 
  1283 
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Table Legends 1284 
Table 1 . Results of Multivariate Analyses of Variance (MANOVAs). In MANOVA-1, the 1285 
dependent variables included z-normalized, rectified scores on the Alzheimer's disease 1286 
Assessment Scale-Cognitive Subscale, Activities of Daily Living, Digit Symbol Substitution Test, 1287 
Semantic Fluency Test, Trail Making Test time and errors (difference Part B-Part A), Digit Span 1288 
length forward and backward, Rey Auditory Verbal Learning Test (learning, delayed recall, 1289 
delayed recognition), Logical Memory story (immediate and delayed recall), Boston Naming 1290 
Test, and Geriatric Depression Scale. In MANOVA-2, the dependent variables include the 1291 
averaged Z-scores of the three cognitive domains (Learning & memory, Dementia severity, 1292 
Executive function). EEG refers to a whole-brain averaged power ratio [(alpha + beta)/(delta + 1293 
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AD < HC, p < .001
AD < T2DM, p = .049











AD < HC, p < .001
AD < T2DM, p = .044






















AD < HC, p < .001
AD < T2DM, p = .021











AD < HC, p < .001
AD < T2DM, p = .063
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